Patents Represented by Attorney Stephen E. Johnson
-
Patent number: 8124611Abstract: The present invention relates to the treatment of KIT dependent diseases that are characterized by a mutant form of KIT whereby the mutant KIT is identified and an appropriate inhibitor of the mutant KIT is administered.Type: GrantFiled: February 4, 2010Date of Patent: February 28, 2012Assignee: Novartis AGInventors: Elisabeth Buchdunger, Doriano Fabbro
-
Patent number: 8124763Abstract: The present invention provides a new method of making compounds of formula (I): wherein R1 is mono- or polysubstituted aryl; R2 is hydrogen, lower alkyl or aryl; and R4 is hydrogen, lower alkyl or halogen.Type: GrantFiled: June 7, 2006Date of Patent: February 28, 2012Assignee: Novartis AGInventors: Wen-Chung Shieh, Joseph McKenna
-
Patent number: 8115016Abstract: The present invention relates to pyrrolidin-2-ones according to the formula (1), or salts thereof, wherein R1 is hydrogen or a nitrogen protecting group, methods for their preparation and their use in the preparation of NEP-inhibitors, particularly in the preparation of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester or salt thereof.Type: GrantFiled: January 10, 2008Date of Patent: February 14, 2012Assignee: Novartis AGInventors: David Hook, Thomas Ruch, Bernhard Riss, Bernhard Wietfeld, Gottfried Sedelmeier, Matthias Napp, Markus Bänziger, Steven Hawker, Lech Ciszewski, Liladhar M Waykole
-
Patent number: 8106081Abstract: The present invention relates to a combination, especially a pharmaceutical composition, comprising as active ingredients (i) an AT1-receptor antagonist or a pharmaceutically acceptable salt thereof; (ii) (a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof or (b) an insulin sensitizer or a pharmaceutically acceptable salt thereof; and, in case of a pharmaceutical composition, a pharmaceutically acceptable carrier.Type: GrantFiled: February 15, 2010Date of Patent: January 31, 2012Assignee: Novartis AGInventors: Malcolm Allison, Marjorie R Gatlin
-
Patent number: 8101659Abstract: The invention relates a pharmaceutical composition comprising a combination of: (i) the AT 1-antagonist valsartan or a pharmaceutically acceptable salt thereof; and (ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or disease selected from the group consisting of hypertension, heart failure, such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, sclerType: GrantFiled: June 27, 2008Date of Patent: January 24, 2012Assignee: Novartis AGInventors: Gary M Ksander, Randy L Webb
-
Patent number: 8058301Abstract: The invention relates to new forms of salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.Type: GrantFiled: December 15, 2004Date of Patent: November 15, 2011Assignee: Novartis AGInventor: Erwin E Marti
-
Patent number: 7943647Abstract: The present invention relates to a method for preparing substituted tetrazoles of the formula or a tautomer or salt thereof, wherein R represents an organic residue. Also provided are compounds obtained according to this method, new reactants and new tetrazole derivatives, useful as pharmaceuticals or agricultural compositions, foaming agents, automotive inflators, and the like.Type: GrantFiled: July 15, 2004Date of Patent: May 17, 2011Assignee: Novartis AGInventor: Gottfried Sedelmeier
-
Patent number: 7799342Abstract: The present invention relates to processes for the preparation of tablets which dissolve rapidly in the mouth and provide an excellent mouthfeel. The tablets of the invention comprise a compound which melts at about 37° C. or lower, have a low hardness, high stability and generally comprise few insoluble disintegrants which may cause a gritty or chalky sensation in the mouth. Convenient and economically feasible processes by which the tablets of the invention may be produced are also provided.Type: GrantFiled: August 19, 2003Date of Patent: September 21, 2010Assignee: Wyeth LLCInventors: Janos Szamosi, Kevin S. Kinter, Vincent H. Li, Khawla Abdullah Abu-Izza
-
Patent number: 7754753Abstract: The present invention is directed to an analgesic composition which consists essentially of a cyclooxygenase-2 inhibitor and a compound selected from the group consisting of non-steroidal anti-inflammatory drugs, acetaminophen and mixtures thereof. The present invention further is directed to a method for inducing analgesia through the administration of such a composition to a patient.Type: GrantFiled: December 13, 2004Date of Patent: July 13, 2010Assignee: Wyeth LLCInventor: Stephen Allen Cooper
-
Patent number: 7652062Abstract: Progesterone receptor modulators of formula I, or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein. These compounds are useful for contraception and hormone replacement therapy. Also provided are products containing these compounds.Type: GrantFiled: September 12, 2007Date of Patent: January 26, 2010Assignee: Wyeth LLCInventors: Casey Cameron McComas, Andrew Fensome, Edward George Melenski
-
Patent number: 7652018Abstract: Compounds of the following structure are described: wherein R1-R6, R10, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.Type: GrantFiled: August 13, 2007Date of Patent: January 26, 2010Assignee: Wyeth LLCInventors: Thomas Joseph Commons, Andrew Fensome, Gavin David Heffernan, Casey Cameron McComas, Richard Page Woodworth, Jr., Michael Byron Webb, Michael Anthony Marella, Edward George Melenski
-
Patent number: 7618990Abstract: Compounds of the following structure are described: wherein R1, R2, R5, R6, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.Type: GrantFiled: August 13, 2007Date of Patent: November 17, 2009Assignee: WyethInventors: Thomas Joseph Commons, Andrew Fensome, Gavin David Heffernan, Casey Cameron McComas, Richard Page Woodworth, Jr., Michael Byron Webb, Michael Anthony Marella, Edward George Melenski, Ronald Charles Bernotas
-
Patent number: 7618989Abstract: Compounds of the following structure are described: wherein R1-R6, R16, m, V, W, X, Y, and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.Type: GrantFiled: August 13, 2007Date of Patent: November 17, 2009Assignee: WyethInventors: Thomas Joseph Commons, Andrew Fensome, Gavin David Heffernan, Casey Cameron McComas, Richard Page Woodworth, Jr., Michael Byron Webb, Michael Anthony Marella, Edward George Melenski, Ronald Charles Bernotas
-
Patent number: 7538107Abstract: Compounds of the following structure are described: wherein R1-R6, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.Type: GrantFiled: August 13, 2007Date of Patent: May 26, 2009Assignee: WyethInventors: Thomas Joseph Commons, Andrew Fensome, Gavin David Heffernan, Casey Cameron McComas, Richard Page Woodworth, Jr., Michael Byron Webb, Michael Anthony Marella, Edward George Melenski, Ronald Charles Bernotas
-
Patent number: 7521552Abstract: There is provided a process for the preparation of substituted amino alcohols HO—(CH2)n—NR1R2 from haloalcohols HO—(CH2)n—X, where X is Cl, Br or I, by reaction with an amine HNR1R2, in water as solvent at a temperature range of about 20° C. to about 90° C. optionally in the presence of a catalytic amount of an iodide source metal iodides. The haloalcohols are useful in the preparation of 6-[(substituted)phenyl]-triazolopyrimidine compounds which are useful in the treatment of cancer.Type: GrantFiled: December 8, 2004Date of Patent: April 21, 2009Assignee: WyethInventors: Yanzhong Wu, Arkadiy Rubezhov, Jean Schmid, Jay Thomas Afragola
-
Patent number: 7507739Abstract: This invention relates to certain 6-[(substituted)phenyl]triazolopyrimidine compounds or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof.Type: GrantFiled: September 24, 2004Date of Patent: March 24, 2009Assignee: WyethInventors: Nan Zhang, Semiramis Ayral-Kaloustian, Thai Nguyen, Yanzhong Wu, Wei Tong
-
Patent number: 7501423Abstract: The invention provides 6-chloro-5-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-2-pyrazin-2-yl-N-[(1S)-2,2,2-trifluoro-1-methylethyl]pyrimidin-4-amine hemifumarate which is a tubulin inhibitor useful in the treatment of cancer and processes of making said hemifumarate.Type: GrantFiled: June 4, 2007Date of Patent: March 10, 2009Assignee: WyethInventors: David Michael Blum, Yanzhong Wu, Jean Schmid, Timothy John Doyle, Jay Thomas Afragola
-
Patent number: 7417148Abstract: Compounds of the formula: wherein: n is an integer from 1-3; X is N, CH, provided that when X is N, n is 2 or 3; R is alkyl of 1 to 3 carbon atoms; R1 is 2,4-diCl, 5-OMe; 2,4-diCl; 3,4,5-tri-OMe; 2-Cl, 5-OMe; 2-Me, 5-OMe; 2,4-di-Me; 2,4-diMe-5-OMe, 2,4-diCl, 5-OEt; R2 is alkyl of 1 to 2 carbon atoms, and pharmaceutically acceptable salts thereof.Type: GrantFiled: November 3, 2004Date of Patent: August 26, 2008Assignee: WyethInventors: Frank Boschelli, Kim T. Arndt, Jennifer M. Golas
-
Patent number: 7402703Abstract: There is herein provided a process for Zr-mediated hydroboration of alkynes which offers (E)-vinylboronic esters in high yield with stereoselectivity and regioselectivity.Type: GrantFiled: June 6, 2006Date of Patent: July 22, 2008Assignee: WyethInventor: Yanong Daniel Wang
-
Patent number: 7399865Abstract: This invention provides compounds of formula 1, having the structure wherein R1, R2, R3, R4, and R5 are described within the specification.Type: GrantFiled: September 10, 2004Date of Patent: July 15, 2008Assignee: WyethInventors: Allan Wissner, Sridhar Krishna Rabindran, Hwei-Ru Tsou